• Home

  • HEALTH CARE

  • HEALTHY LIFESTYLE

  • HYGIENE

  • COSMETICS

  • FOR HIM

  • PREGNANCY AND MOTHERHOOD

  • CHILD

    2. HEALTH CARE
    3. Diclofenac Natrii (Diclofenac sodium) solution for injections 2.5% in ampoules of 3 ml, 10 pcs — Made in Ukraine — Free Delivery

    Diclofenac Natrii (Diclofenac sodium) solution for injections 2.5% in ampoules of 3 ml, 10 pcs — Made in Ukraine — Free Delivery


    Brand: OJSC Lubnypharm
    Product Code: Diclofenac Natrii
    Availability: In Stock
    $18.69
    Add to Cart

    Product description

    Diclofenac sodium is a non-steroidal anti-inflammatory and anti-rheumatic agent.
    The preparation for intramuscular administration is intended for the treatment of:
    • inflammatory and degenerative forms of rheumatism, rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, spondyloarthritis, vertebral pain syndrome, non-articular rheumatism;
    • acute attacks of gout;
    • renal and biliary colic;
    • pain and swelling after injuries and operations;
    • severe migraine attacks.
    The preparation, when administered as an intravenous infusion, is intended for the treatment or prevention of postoperative pain.

    Storage

    active substance: diclofenac;
    1 ml of solution contains diclofenac sodium 25 mg;
    excipients: mannitol, sodium metabisulfite (E 223), benzyl alcohol, propylene glycol, 1 M sodium hydroxide solution, water for injections.

    Contraindication

    Hypersensitivity to diclofenac, sodium metabisulfite or any other components of the preparation.
    History of bleeding or perforation of the digestive tract associated with previous treatment with non-steroidal anti-inflammatory preparations (NSAIDs).
    Active peptic ulcer/bleeding or a history of recurrent peptic ulcer/bleeding (two or more separate episodes of established ulceration or bleeding).
    Like other NSAIDs, diclofenac is contraindicated in patients in whom the use of ibuprofen, acetylsalicylic acid or other non-steroidal anti-inflammatory preparations provokes attacks of bronchial asthma, angioneurotic edema, urticaria, acute rhinitis/nasal polyps, bronchospasm or other allergic reactions.
    Inflammatory bowel diseases (for example, Crohn's disease or ulcerative colitis).
    Acute stomach or intestinal ulcer; gastrointestinal bleeding or perforation.
    Treatment of perioperative pain in coronary artery bypass grafting (or the use of an artificial blood circulation device).
    Ischemic heart disease in patients with angina pectoris and myocardial infarction.
    Cerebrovascular diseases in patients who have suffered a stroke or have episodes of transient ischemic attacks.
    Diseases of peripheral arteries.
    In this dosage form, the preparation is contraindicated for children.
    III trimester of pregnancy.

    Adverse reactions

    From the hematopoietic system: thrombocytopenia, leukopenia, anemia (including hemolytic and aplastic anemia), agranulocytosis.
    From the side of the immune system: hypersensitivity, anaphylactic and anaphylactoid reactions (including arterial hypotension and shock), angioedema (including facial edema).
    From the mental side: disorientation, depression, insomnia, insomnia, nightmares, irritability and other mental disorders.
    From the side of the nervous system: headache, dizziness, drowsiness, fatigue, paresthesia, memory impairment, convulsions, anxiety, tremor, aseptic meningitis, taste disorder, stroke, confusion, hallucinations, sensitivity disorders, general malaise.
    On the part of the organs of vision: vision disorder, blurred vision, diplopia, optic neuritis.
    On the part of hearing organs: vertigo, ringing in the ears, hearing impairment.
    From the cardiovascular system: palpitations, chest pain, heart failure, myocardial infarction, arterial hypertension/hypotension, vasculitis, Kounis syndrome.
    From the respiratory system: asthma (including dyspnea), bronchospasm; pneumonitis
    From the digestive tract: nausea, vomiting, diarrhea, dyspepsia, abdominal pain, flatulence, anorexia, gastritis, gastrointestinal bleeding, vomiting with blood impurities, hemorrhagic diarrhea, melena; stomach or intestinal ulcers with or without bleeding or perforation (sometimes fatal, especially in elderly patients) that may lead to peritonitis; colitis (including hemorrhagic colitis and exacerbation of ulcerative colitis or Crohn's disease), constipation, stomatitis (including ulcerative stomatitis), glossitis; pharyngeal disorder similar to the diaphragm of intestinal structures; esophageal disorders, membranous intestinal strictures, pancreatitis; ischemic colitis.
    From the side of the hepatobiliary system: an increase in the level of transaminases, hepatitis, jaundice, impaired liver function, acute hepatitis, hepatonecrosis, liver failure.

    Application method

    The dose should be selected individually, starting with the minimum effective dose, and should be taken for the shortest possible time.
    Diclofenac Sodium, solution for injection, is not used for longer than 2 days. If necessary, the treatment can be continued with diclofenac tablets or suppositories.
    Each ampoule is intended for single use only. The solution should be used immediately after opening the ampoule. Any unused content must be disposed of.
    Intramuscular injection
    In order to prevent damage to nerves or other tissues at the site of intramuscular injection, the following rules must be followed.
    The dose is usually 75 mg (1 ampoule) per day by deep injection into the upper outer sector of the gluteus maximus muscle. In severe cases (for example, colic), the daily dose can be increased to two injections of 75 mg, between which an interval of several hours should be observed
    (one injection in each buttock). As an alternative, 75 mg of the solution can be combined with other dosage forms of the preparation (for example, tablets, suppositories) up to a total maximum daily dose of 150 mg of diclofenac sodium.
    In the conditions of a migraine attack, clinical experience is limited to cases with the initial use of 1 ampoule of 75 mg, the dose is administered, if possible, immediately after using suppositories of 100 mg on the same day (if necessary). The total daily dose should not exceed 175 mg on the first day.
    There are no available data on the use of diclofenac for the treatment of migraine attacks for more than one day.
    Intravenous infusions
    Diclofenac Sodium, solution for injection, should not be administered as an intravenous bolus injection.
    Immediately before starting the intravenous infusion of diclofenac, depending on its required duration, it should be diluted in 100-500 ml of 0.9% sodium chloride solution or 5% glucose solution buffered with sodium bicarbonate solution for injection (0.5 ml of 8.4% solution or 1 ml of 4.2% or the corresponding volume of another concentration), taken from a newly opened container; add the contents of 1 ampoule of the preparation to this solution. Only clear solutions can be used. If there are crystals or sediment in the solution, it cannot be used for infusion.

    Features of application

    Use during pregnancy or breastfeeding
    Like other NSAIDs, the preparation is contraindicated in the 3rd trimester of pregnancy (possible inhibition of uterine contractility and premature closure of the ductus arteriosus in the fetus).
    If diclofenac is used in women trying to get pregnant or in the first trimester of pregnancy, the dose of the preparation should be as low as possible, and the duration of treatment should be as short as possible.
    Breastfeeding period. Like other NSAIDs, diclofenac passes into breast milk in small amounts. Thus, to avoid unwanted effects on the infant, diclofenac should not be used during breastfeeding. If treatment is absolutely necessary, breast-feeding should be stopped.
    Children
    The preparation in this medicinal form is not used for children.
    The ability to influence the speed of reaction when driving vehicles or other mechanisms
    Patients who experience visual impairment, dizziness, vertigo, drowsiness or other central nervous system disturbances, lethargy or fatigue during treatment with diclofenac should refrain from driving or operating machinery.

    Overdose

    There is no typical clinical picture of the consequences of an overdose of diclofenac.
    Symptoms: nausea, vomiting, epigastric pain, gastrointestinal bleeding, diarrhea, dizziness, headache, disorientation, agitation, coma, drowsiness, tinnitus, loss of consciousness or convulsions. In case of severe poisoning, acute kidney failure and liver damage are possible.
    Treatment. Treatment of acute NSAIDs poisoning consists primarily of supportive measures and symptomatic treatment. Supportive measures and symptomatic treatment are necessary to eliminate such complications as arterial hypotension, renal failure, convulsions, gastrointestinal disorders and respiratory depression.
    Within 1 hour after administration of a potentially toxic amount of the preparation orally, the possibility of using activated charcoal should be considered. In addition, in adults, gastric lavage should be considered for 1 hour after administration of a potentially toxic amount of the preparation. Diazepam should be administered intravenously in case of frequent or prolonged convulsions.
    Special measures, such as forced diuresis, dialysis or hemoperfusion, cannot guarantee the elimination of NSAIDs due to their high binding to blood plasma proteins and intensive metabolism.

    Storage conditions

    Store in the original packaging at a temperature not higher than 25 °C.
    Keep out of the reach of children.

    There are no reviews for this product.
    VEV Healthcare Store © 2017